Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth A Eisenhauer

Showing results (1-10 of 60) with videos related to

Pageof 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 29, 2012
Progression-free survival: meaningful or simply measurable?Christopher M Booth, Elizabeth A Eisenhauer
Journal of the National Cancer Institute|July 9, 2004
Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practiceWendy R Parulekar, Elizabeth A Eisenhauer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2008
Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase IIIRobert H El-Maraghi, Elizabeth A Eisenhauer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2022
The Time Toxicity of Cancer TreatmentArjun Gupta, Elizabeth A Eisenhauer, Christopher M Booth
Nature Biotechnology|March 11, 2021
Medical students need artificial intelligence and machine learning trainingAidan Pucchio, Elizabeth A Eisenhauer, Fabio Ynoe Moraes
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
Call for clarity in the reporting of benefit associated with anticancer therapiesChristopher M Booth, Pavlo Ohorodnyk, Elizabeth A Eisenhauer
European Journal of Cancer (Oxford, England : 1990)|June 24, 2009
Clinical benefit in oncology trials: is this a patient-centred or tumour-centred end-point?Pavlo Ohorodnyk, Elizabeth A Eisenhauer, Christopher M Booth
JAMA Oncology|July 3, 2020
Covid-19 Pandemic-An Opportunity to Reduce and Eliminate Low-Value Practices in Oncology?Bishal Gyawali, Bishesh Sharma Poudyal, Elizabeth A Eisenhauer
European Journal of Cancer (Oxford, England : 1990)|June 30, 2014
Progression-free survival as an end-point in solid tumours--perspectives from clinical trials and clinical practiceAndrew G Robinson, Christopher M Booth, Elizabeth A Eisenhauer
European Journal of Cancer (Oxford, England : 1990)|June 17, 2014
Disease-free survival as an end-point in the treatment of solid tumours--perspectives from clinical trials and clinical practiceAndrew G Robinson, Christopher M Booth, Elizabeth A Eisenhauer
Pageof 6

Showing results (1-10 of 60) with videos related to

Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 29, 2012
Progression-free survival: meaningful or simply measurable?Christopher M Booth, Elizabeth A Eisenhauer
Journal of the National Cancer Institute|July 9, 2004
Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practiceWendy R Parulekar, Elizabeth A Eisenhauer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2008
Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase IIIRobert H El-Maraghi, Elizabeth A Eisenhauer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2022
The Time Toxicity of Cancer TreatmentArjun Gupta, Elizabeth A Eisenhauer, Christopher M Booth
Nature Biotechnology|March 11, 2021
Medical students need artificial intelligence and machine learning trainingAidan Pucchio, Elizabeth A Eisenhauer, Fabio Ynoe Moraes
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
Call for clarity in the reporting of benefit associated with anticancer therapiesChristopher M Booth, Pavlo Ohorodnyk, Elizabeth A Eisenhauer
European Journal of Cancer (Oxford, England : 1990)|June 24, 2009
Clinical benefit in oncology trials: is this a patient-centred or tumour-centred end-point?Pavlo Ohorodnyk, Elizabeth A Eisenhauer, Christopher M Booth
JAMA Oncology|July 3, 2020
Covid-19 Pandemic-An Opportunity to Reduce and Eliminate Low-Value Practices in Oncology?Bishal Gyawali, Bishesh Sharma Poudyal, Elizabeth A Eisenhauer
European Journal of Cancer (Oxford, England : 1990)|June 30, 2014
Progression-free survival as an end-point in solid tumours--perspectives from clinical trials and clinical practiceAndrew G Robinson, Christopher M Booth, Elizabeth A Eisenhauer
European Journal of Cancer (Oxford, England : 1990)|June 17, 2014
Disease-free survival as an end-point in the treatment of solid tumours--perspectives from clinical trials and clinical practiceAndrew G Robinson, Christopher M Booth, Elizabeth A Eisenhauer
Pageof 6